Nolia

Quick links to important sections

Nolia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nolia

This introductory section establishes the core identity, classification, composition, and general purpose of the prescription medicine Nolia.

Property Description
Active Ingredient Cefpodoxime proxetil (Prodrug)
Active Metabolite Cefpodoxime
Pharmacological Class Third-Generation Cephalosporin Antibiotic
Form Oral Tablets, Oral Suspension
Origin Semi-synthetic (Beta-lactam derivative)
Rx Status Prescription-only medicine (Rx-only)

What Type of Antibiotic is Nolia (Cefpodoxime)?

Nolia is a prescription-only semi-synthetic antibiotic that contains the active substance cefpodoxime proxetil, classifying it as a third-generation cephalosporin. This class of medicine belongs to the larger group of beta-lactam antibiotics, structurally defined by a chemical ring crucial for its bactericidal effect. The brand Nolia is often associated with the manufacturer Shinto Organics or Astonea Labs and is generally positioned for systemic control of bacterial infections.

The active component is engineered as a prodrug, meaning the cefpodoxime proxetil compound itself is inactive when administered orally but is efficiently converted into the fully active agent, cefpodoxime, once it is absorbed by the body. This specific chemical structure provides enhanced stability against certain bacterial enzymes, a factor that expands its usefulness compared to earlier antibiotics.


Understanding the Forms and Core Action of Nolia

The primary purpose of Nolia is the systemic elimination of specific harmful bacteria causing infection, such as those that might cause respiratory tract illnesses. The medication is specifically designed for oral administration and is available in two main dosage forms: film-coated tablets and a granular form for preparing an oral suspension.

Cefpodoxime's mechanism involves directly interfering with the ability of bacteria to maintain their cell wall structure, which is necessary for their survival. The drug’s broad-spectrum capability includes effectiveness against a wide array of susceptible Gram-positive and Gram-negative organisms, making it a tool for controlling the microbial source of an illness.

Regulatory References

  1. NIH DailyMed: Cefpodoxime Information

What side effects are possible with Nolia?

Possible Side Effects and Safety Information

The safety profile of Nolia, as documented in official government regulatory labels (e.g., FDA/EMA), establishes the known risks by grouping adverse reactions according to frequency and body system.

Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions observed during clinical studies are generally mild to moderate and are officially classified as Very Common or Common. These expected reactions typically involve the following System-Organ Classes (SOC):

  • Gastrointestinal Disorders: Often including nausea and abdominal discomfort.
  • Nervous System Disorders: Such as headache or temporary dizziness.

Reactions categorized as Uncommon, Rare, or Very Rare are also documented. These lower-frequency events are essential for post-marketing surveillance and risk management, as they may include serious or unexpected reactions.

Serious Adverse Reactions and Restrictions

Official regulatory information highlights specific serious adverse reactions that require immediate medical attention. The label may include warnings regarding potentially life-threatening conditions or events leading to hospitalization, which are reported to national and international pharmacovigilance systems for continuous assessment.

The regulatory label specifies Contraindications—situations where Nolia must not be used—which often include known hypersensitivity to the active substance or certain excipients. The documentation also details Special Warnings and Precautions, such as the need for cautious use in patients with pre-existing organ impairment (e.g., renal or hepatic function), or specific drug-drug interaction risks.

Population-Specific Safety Notes

Where applicable, official governmental documents include safety considerations for specific patient groups. These may cover formal statements regarding the use of Nolia during pregnancy or while breastfeeding, often advising caution or recommending risk-mitigation strategies. Furthermore, any differences in the safety profile or the need for specific monitoring in pediatric or geriatric patients are formally documented in the official prescribing information.

Overdose and Emergency Response

A suspected overdose of Nolia (Cefpodoxime proxetil) requires immediate emergency medical attention, as officially documented by regulatory authorities. Overdose manifestations typically include severe gastrointestinal symptoms such as nausea, vomiting, diarrhea, and stomach pain. A more serious, documented clinical outcome is encephalopathy, a neurological condition associated with high and prolonged drug concentrations in the bloodstream. This specific risk is noted to be heightened in patients with renal insufficiency due to impaired drug clearance, as stated in official labeling.

Regulatory guidance mandates that emergency medical services must be contacted immediately if severe, life-threatening signs are observed, including collapse, seizure, trouble breathing, or inability to be awakened. Management is based on supportive and symptomatic therapy, as no specific antidote is known for Cefpodoxime. In cases requiring active drug removal, hemodialysis is documented as a procedural option, capable of clearing a substantial portion of the drug from the system. The documented encephalopathy is generally reversible once drug concentrations in the plasma decline.

Therapeutic Uses of Nolia

What Nolia Treats: Main Uses and Benefits

Nolia may be part of symptomatic management across domains where additional symptomatic support is needed. It is applied in clinical settings that involve acute or disruptive symptom patterns, targeting conditions such as Community-Acquired Pneumonia, bronchitis, Acute Maxillary Sinusitis, and Acute Otitis Media (AOM), as well as uncomplicated urinary tract infections (UTIs) and skin and soft tissue infections. This therapeutic scope encompasses these clinical applications.

The medication helps address symptom clusters that may become intense or disruptive, including symptoms related to systemic imbalance, symptoms that interfere with daily functioning, and symptoms related to inflammatory or irritative states. It is considered relevant for use in both adult and pediatric patients (two months and older).

“Nolia provides support that contributes to improved day-to-day comfort during these symptomatic periods, helping to ease the overall burden of infection-related distress.”

This supportive treatment is relevant when supportive symptom management is appropriate and is commonly used across conditions presenting with systemic or localized discomfort. Overall, Nolia assists with maintaining functional stability during episodes of heightened physiological stress.

Quick Fact: Relief for symptoms associated with acute or episodic changes

Regulatory References

  1. NIH MedlinePlus overview of Cefpodoxime

Eligibility and Restrictions for Use

Nolia is approved for use in adults who wake up at least two times per night to urinate due to nocturnal polyuria (overproduction of urine at night).

Populations Who Must Not Use Nolia (Contraindicated)

Due to the risk of severe hyponatremia (low sodium levels), Nolia is strictly prohibited for patients with:

  • Hyponatremia (or a history of it).
  • Polydipsia (excessive thirst).
  • Severe or moderate renal impairment (kidney disease, specifically if estimated GFR is less than 50 mL/min/1.73 m^2).
  • Congestive heart failure (NYHA Class II–IV) or uncontrolled hypertension.
  • Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH).
  • Illnesses that cause fluid/electrolyte imbalance (e.g., systemic infection, gastroenteritis).
  • Primary nocturnal enuresis (bedwetting) in adults and children.

Other Restrictions and Considerations

  • Age: Use is not studied in adults under 50. Older adults (age 65 and up) require a specific, lower starting dose due to increased risk of hyponatremia.
  • Pregnancy/Lactation: Use during pregnancy is not recommended.
  • Drug Interactions: Nolia must not be used concomitantly with loop diuretics (e.g., furosemide) or systemic/inhaled glucocorticoids.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nolia's interaction profile is based on substances that affect the active metabolite's absorption or clearance. No specific drug-drug or drug-substance combination is formally listed as contraindicated in regulatory documents.

Classification Interacting Agents
Exposure Reduction Gastric pH-elevating agents (Antacids, H2-receptor antagonists)
Exposure Increase Probenecid
Pharmacodynamic Risk Nephrotoxic Drugs, Oral Anticoagulants

Exposure Reduction: Co-administration with antacids or H2-receptor antagonists (e.g., Cimetidine) reduces the overall extent of absorption of Cefpodoxime, thus lowering plasma concentrations. Regulatory text advises that gastric pH-elevating agents should be administered 2 to 3 hours after Nolia to mitigate this effect. Exposure Increase: Probenecid inhibits the renal excretion of Cefpodoxime, resulting in an officially documented increase of systemic exposure ( AUC) by approximately 31% [NIH DailyMed: Cefpodoxime Information]. Pharmacodynamic Risk: Caution and monitoring are advised with Nephrotoxic Drugs and Oral Anticoagulants due to potential additive risks to renal function and enhanced anticoagulant effects, respectively [SmPC]. The tablet form is noted to have enhanced absorption when administered with food.

Mechanism of Action

How Nolia Works


Selective Blocking of mathbfA2A Receptors

Nolia's mechanism of action is centered on its function as a selective antagonist of the adenosine A2 A receptors. These receptors are expressed in high density within the striatum, a central component of the brain's motor circuitry. Nolia initiates its pharmacodynamic effect by binding to and blocking these specific receptors. This interaction directly interrupts the signaling of endogenous adenosine within the adenosinergic system, thereby setting off a cascade of downstream effects that modulate motor regulation.


Modulating the Motor Control Pathway

Nolia's targeted action is leveraged to adjust the neural signaling balance within the basal ganglia motor circuit. By reducing signaling that originates in the A2 A receptor-associated indirect pathway (the pathway that provides inhibitory control of motor output), Nolia shifts the circuit balance toward greater motor pathway facilitation. This fundamental physiological adjustment results in a more sustained and regulated transmission of motor commands, which subsequently influences the resultant motor system physiological state.

Dosage and Administration Information

How to Use Nolia

Nolia (cefpodoxime proxetil) is administered via the oral route and is available as film-coated tablets and granules for oral suspension. The standard adult dosing schedule requires taking the medicine twice daily, approximately every 12 hours, for the prescribed duration. The specific amount taken per dose ranges from 100 mg to 400 mg, which is determined by the clinical scenario being addressed.


Administration and Timing

Feature Procedural Guideline
Dosing Frequency Twice daily (every 12 hours) for most uses.
Tablets and Food Film-coated tablets must be taken with food to achieve proper absorption.
Oral Suspension May be taken with or without food, but must be shaken well before each use.

The total treatment course is a fixed duration that is dependent on the infection, typically ranging from 5 days for conditions such as pharyngitis up to 14 days for more extensive infections. The full course must be completed, even if the patient's condition appears resolved earlier. If a dose is missed, the patient is instructed to skip it if it is nearly time for the next scheduled dose; the use of a double dose to compensate is prohibited.

Population-Specific Use

High-level adjustments apply to specific populations. Pediatric patients (from 2 months to 12 years) receive a weight-based dose of 5 mg/ kg every 12 hours. For adults with moderate to severe renal impairment (creatinine clearance less than 30 mL/ min), the standard 12-hour interval between doses is extended to 24 hours. No specific dose adjustment is required for patients with hepatic impairment.

Recent Clinical Evidence

Official summaries of the evidence for Nolia (cefpodoxime) are derived from formal scientific research, primarily randomized controlled trials (RCTs) and systematic reviews, which explore the drug's use in various community-acquired bacterial infections. This overview describes what researchers have studied, what their findings indicate, and where the limitations of the evidence lie, without offering any clinical advice or recommendations.

Evidence for Use in Acute Otitis Media (AOM) and Sinusitis

Nolia was the subject of research exploring Acute Otitis Media (AOM) and Acute Maxillary Sinusitis. The evidence for AOM largely comes from comparative clinical trials conducted in pediatric patients, focusing on clinical response rates and the bacteriological clearance rate (the study measure of bacterial presence). Similarly, in Acute Maxillary Sinusitis, research examined short-term symptom changes, focusing on clinical outcomes and radiographic findings.

Certainty remains low regarding long-term outcomes for both conditions, as follow-up durations were limited in many key studies.

Research Examining Lower Respiratory Tract Infections (CAP and Bronchitis)

Nolia was evaluated in settings involving lower respiratory tract infections, particularly Community-Acquired Pneumonia (CAP) and Acute Exacerbations of Chronic Bronchitis (AECB). Studies explored Nolia as an oral therapy for non-severe disease and as part of step-down care. The research monitored outcomes related to systemic imbalance, and examined metrics related to both clinical response and the rate of bacterial clearance.

A key research limitation is that the studies predominantly focused on mild to moderate CAP, meaning data are still emerging regarding Nolia's performance in severe cases.

Research Examining Localized Infections (UTIs and Skin) and Special Populations

Research has explored Nolia's utility in Uncomplicated Urinary Tract Infections (UTIs) and Skin and Soft Tissue Infections (SSTIs), monitoring microbiological and clinical response measures. A major research limitation for SSTIs is that the findings are not applicable to infections caused by certain common resistant pathogens like Methicillin-Resistant S. aureus ( MRSA).

Specific research was conducted on pediatric patients and patients with impaired renal (kidney) function. These PK/PD studies described patterns related to the drug's systemic clearance, which appears to be slower in patients with reduced kidney function. However, the evidence base for Nolia use in pregnancy or for patients with severe pre-existing hepatic (liver) impairment is not fully established.

Long-Term Evidence and Research Gaps

The body of research evidence primarily focuses on the short-term outcomes of acute infectious episodes. As is common with short-course antibiotic trials, long-term effects are not fully established, and research provides limited insight into the durability of the response. The evidence highlights that comparative evidence is lacking for Nolia against certain modern antibiotics, and ongoing surveillance may be necessary to contextualize its use alongside evolving bacterial susceptibility.

Key Studies & References

  1. CEFPODOXIME PROXETIL tablet, film coated (DailyMed/NIH Drug Label)
  2. Cefpodoxime: MedlinePlus Drug Information (Overview of Indications and Use)
  3. Pharmacokinetics of cefpodoxime in children with normal and impaired renal function (Example PK/PD Study)

Frequently Asked Questions (FAQ)

Common questions about Nolia (FAQ)

Q: Is Nolia safe to take if I have liver problems?

A: According to the official product information, no specific dose adjustment is typically required for patients with liver problems (hepatic impairment). However, regulatory guidance indicates a need for close monitoring for individuals with pre-existing liver disease. This approach is described as aligning with established clinical protocols.

Q: Are there any foods I should avoid while using Nolia?

A: Regulatory guidance states that Nolia tablets is required to be taken with food to maximize the medicine's absorption. Some official patient advisories advise a potential limitation of foods and juices, such as grapefruit juice, that are high in minerals like calcium. These substances have the potential to hinder the absorption of some antibiotics.

Q: Why is Nolia only available by prescription?

A: Nolia is a prescription-only antibacterial drug. This status is intended to ensure the use of the medicine is limited to treating proven or strongly suspected bacterial infections. This official control helps prevent the medicine from being misused, which is a key factor in reducing the risk of developing drug-resistant bacteria.

Q: What is the full list of ingredients in Nolia?

A: The active substance in Nolia is cefpodoxime proxetil. Regulatory documents list all other inactive components, known as excipients, for each form of the medicine. For instance, the film-coated tablets often contain ingredients such as lactose monohydrate.

Q: Is it necessary to take Nolia at the exact same time every day?

A: Official dosing guidelines indicate the medicine is designated for administration at around the same times every day to support optimal drug effectiveness. Since the dosing is usually twice daily (every 12 hours), consistency in timing helps maintain a stable and effective level of the drug in the body.

Q: What should I do if a side effect of Nolia won't go away?

A: Official documents describe the need for prompt reporting to a healthcare provider if any side effects, such as a headache or nausea, last or get worse. This is also critical if any serious adverse reactions occur, as these are described in the documentation as needing immediate medical attention.

Q: Do I need to change my diet while taking Nolia?

A: The tablet form of Nolia is designated for administration with food to ensure the drug is properly absorbed. Patient advisories also suggest that dietary considerations may involve the addition of probiotic-rich foods to manage potential digestive side effects. Regulatory guidance recommends discussion of any significant dietary changes with a healthcare provider.

Q: How quickly should I expect Nolia to start working?

A: Studies on the drug’s behavior in the body indicate that the active drug, cefpodoxime, is absorbed quickly after taking a dose. The time required to reach the highest drug concentration in the bloodstream (Tmax) is approximately 2 to 3 hours in healthy individuals. This suggests the medicine is available to act quickly.

Q: Can Nolia be taken with common vitamins or supplements?

A: The official product information advises caution when Nolia is taken alongside supplements containing high levels of certain minerals. For example, specific regulatory interaction data lists calcium and Vitamin D as needing consideration. Regulatory guidance recommends discussion of all supplements with a healthcare provider before starting Nolia.

Q: Does Nolia cause fatigue or sleepiness?

A: Regulatory documents list several nervous system disorders among the potential adverse reactions. These include sleepiness (or unusual drowsiness) and extreme fatigue as possible, though generally uncommon, side effects. Official documentation indicates that due to these effects, caution is warranted when performing tasks requiring alertness.

Q: How long does Nolia stay in your system after stopping it?

A: Pharmacokinetics studies show that the active drug has an average elimination half-life ( T1/2) of approximately 2.2 hours in healthy people. This means that half of the drug is cleared from the blood every 2.2 hours. Consequently, the drug is largely cleared from the body within about 12 hours of the final dose.

Q: Why does the packaging say to avoid grapefruit juice with Nolia?

A: While not listed as a formal drug-food interaction, official patient advisories advise a potential limitation of specific fruit juices, such as grapefruit juice. This is because these juices contain certain components that may potentially interfere with the absorption of the antibiotic, leading to slightly lower drug levels.

Q: Can Nolia be taken by someone who is lactose intolerant?

A: Official drug labels confirm that the film-coated tablet form of Nolia contains lactose anhydrous or lactose monohydrate as an inactive ingredient. This presence is a factor for consideration by individuals with lactose intolerance, and they may need to discuss alternative forms.

Q: Can I drive while taking Nolia?

A: Regulatory documents include a warning that Nolia may cause dizziness, which could affect the ability to drive or operate machinery. Regulatory warnings describe the need for individuals to understand the drug's effects on them before attempting to drive or perform complex tasks.

Q: What if I take Nolia and then drink a small amount of alcohol?

A: Official patient information advises a potential limitation of alcohol consumption during the treatment course. This precaution is advised to prevent potential unpleasant side effects, although regulatory sources indicate the direct risk of a severe drug-alcohol interaction is generally considered low.

Q: Is Nolia considered a controlled substance?

A: No. Nolia (cefpodoxime proxetil) is officially classified by regulatory bodies as a non-controlled medication. This means it is not subject to the specific prescribing and dispensing restrictions that apply to controlled substances due to addiction or abuse potential.

Q: Can Nolia make anxiety worse?

A: The official documentation lists mental/mood changes (such as confusion) as a possible serious adverse reaction that has been reported. This provides an indirect basis for discussing potential psychological effects, and official documents describe the need to report any noticeable changes in mood promptly to a healthcare professional.

Q: Can Nolia cause changes in mood?

A: Official regulatory documents list mental/mood changes (such as confusion) as a possible serious side effect that has been observed. Although uncommon, official documents describe the need for any persistent or significant change in emotional state to be considered for immediate medical attention.

Q: Is Nolia a biologic medicine?

A: No. Nolia (cefpodoxime proxetil) is classified as an extended spectrum, semi-synthetic antibiotic of the cephalosporin class, which is a small-molecule drug. This means it is manufactured through chemical synthesis rather than biological sources or processes used for biologic medicines.

Q: Are there any common misuses of Nolia that people should know about?

A: Regulatory guidelines emphasize two key risks of misuse: not completing the full prescribed course of therapy and taking the drug for viral infections (like the common cold). Both practices increase the public health risk of developing antibiotic resistance.

Q: Does Nolia affect fertility in men or women?

A: Based on current regulatory-based patient information and non-clinical data, there is no scientific evidence to indicate that Nolia (cefpodoxime proxetil) affects fertility.

Q: Is Nolia a new drug, or has it been around for a while?

A: The active substance in Nolia, Cefpodoxime proxetil, was originally approved by the FDA in August 1992. This indicates that the medicine has been available and in use for a significant period.

How should Nolia be stored and disposed of?

Storage Conditions for Nolia (Cefpodoxime Proxetil)

The required storage conditions for Nolia vary by form to maintain product stability. Tablets and the dry powder for suspension must be stored at controlled room temperature (20 C to 25 C), protected from light and excess moisture. All forms must be kept in the tightly closed original container and placed out of the sight and reach of children.

Product Form Temperature Requirement Stability Constraint
Tablets / Dry Powder Controlled Room Temperature Do not freeze
Reconstituted Liquid Refrigerated (2 C to 8 C) Must be discarded after 14 days and not frozen

Disposal Instructions

Unused or expired Nolia should be discarded via a drug take-back program. If a program is unavailable, the medicine must be mixed with an undesirable substance, placed in a sealed container, and then thrown into the household trash. Nolia is not recommended for disposal by flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nolia found in:

A-Z Index: